logo
AHCS | Information Portal<p>The AHCS Information Portal is your one stop information area consisting of the Information Station & Health Hub.</p>AHCS | My CommunityAHCS | Support Forums
Treatment News
Title Filter     Display # 
# Article Title Author Hits
1 Telaprevir May Be Viewed More Positively by Clinicians Than Boceprevir for Hepatitis C Virus Treatment Following Their Launches In 2011 Linda McInnes 63
2 Achillion Pharma At A Glance Linda McInnes 118
3 Engineering a new way to study hepatitis C Linda McInnes 73
4 Potential New Class of Drugs to Combat Hepatitis C Identified Linda McInnes 64
5 New tests for ‘silent killer’ urged Linda McInnes 97
6 A Larger Proportion of Hepatitis C Non-Responder Patients Will Be Treated with Telaprevir Than Boceprevir Linda McInnes 114
7 Is Pegasys Superior to PEG-Intron for Hep C Treatment? AHCS Team 92
8 Natural compound may help treat hepatitis C infection AHCS Team 196
9 New Hepatitis C Treatment Shows Promise AHCS Team 203
10 Spontaneous HCV Clearance in Children AHCS Team 56
11 Treatment Response in Older Patients AHCS Team 75
12 Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C AHCS Team 82
13 Sydney Research 217
14 UPDATE 2-InterMune to modify hep C study to drop one dosage AHCS Team 111
15 Hep C in kids goes undetected: study AHCS Team 108
16 Schering-Plough reports data on hepatitis C drug AHCS Team 137
17 What Is the Optimal Timing of Hepatitis C Antiviral Therapy Before and After Liver Transplantation? Presented at AASLD AHCS Team 100
18 INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227 AHCS Team 142
19 More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen AHCS Team 130
20 Vertex Hepatitis C Drug Wipes Out Virus For Toughest-to-Treat Patients AHCS Team 183
21 Vertex drug helps hepatitis C patients AHCS Team 77
22 SciClone Announces Enrollment Of First Patient In Its Phase 2 Trial Of SCV-07 In Hepatitis C AHCS Team 108
23 Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting AHCS Team 816
24 Relapse common in HIV/HCV co-infected patients after treatment for HCV AHCS Team 123
25 Short Strand of RNA May Help Predict Survival and Response to Treatment for Patients with Liver Cancer AHCS Team 122
26 Idera launches Phase 1 Hepatitis C trial AHCS Team 123
27 Committee For Medicinal Products For Human Use Post-Authorisation Summary Of Positive Opinion For Rebetol AHCS Team 158
28 Retreatment Benefits Some Hepatitis C Non-Responders AHCS Team 165
29 Medtronic's COPE-HCV clinical study commences AHCS Team 224
30 Is endotoxin receptor CD14 rs2569190/C-159T gene correlated with chronic hepatitis C? AHCS Team 190
31 Nymox's NX-1207 Shows Major Effect On Liver Cancer AHCS Team 209
32 Genes Tied to Gap in Treatment of Hepatitis C AHCS Team 184
33 Eiger Initiates Dosing In CLEAN-1 HCV Phase 1b Trial AHCS Team 220
34 Hepatitis C Infection: Treatment Options Equally Effective, Likelihood Of Success Known Early On AHCS Team 240
35 Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia AHCS Team 194
36 Head-to-Head Trial Finds HCV Regimens Equal AHCS Team 277
37 Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron® in Chronic Hepatitis C AHCS Team 247
38 Controversy: Ozone Therapy for HCV AHCS Team 300
39 Natural Course of Treated and Untreated Chronic HCV Infection AHCS Team 208
40 Croat with two strains of hepatitis has recovered without treatment AHCS Team 281
41 Kids with hepatitis go without treatment AHCS Team 254
42 Shorter & More Effective: Triple Drug Treatment for Hepatitis C AHCS Team 314
43 Synthetic Interferon May Be Useful for Hep C Retreatment AHCS Team 231
44 Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C AHCS Team 215
45 Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting AHCS Team 299
46 Amarillo Biosciences Supplies Oral Interferon for Taiwanese Hepatitis C Study AHCS Team 191
47 Merck Announces Interim Phase IIa Study Results of MK-7009 AHCS Team 467
48 First Evidence For DNA-based Vaccination Against Chronic Hepatitis C AHCS Team 272
49 Medivir: New Phase IIa Data on TMC435 in Patients with Hepatitis C Presented at the Ongoing EASL - Meeting AHCS Team 245
50 UPDATE 2-Schering hepatitis C drug shines, but anemia seen AHCS Team 299
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  Next 
  •  End 
  • »
Page 1 of 7